Desk›Healthcare› Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd
BSE 507789 · NSE JAGSNPHARM · ISIN INE048B01035 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹238.20
-1.77%
BSE close, 28 August 2026
₹1,570.44 cr
6.6 cr shares · Micro cap
₹414.38 cr
as published
34.5× · 7.96×
EPS ₹6.91 · BV ₹29.92
287.23 / 43.08
₹ cr, as filed
28
9 selected · 32%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -10.0% |
|---|---|
| Against 52-week low | +53.8% |
| Day change | -1.77% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹6.91 |
|---|---|
| Price / earnings | 34.47× |
| Price / book | 7.96× |
| Book value — derived, price ÷ P/B | ₹29.92 |
| Return on equity | 23.07% |
| Operating margin | 24.41% |
| Net margin | 16.04% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 23.09%
- ROE as published
- 23.07%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 82.23 | 13.19 | 2.00 | 24.41% | 16.04% |
| Mar-26 · Q | 64.20 | 8.76 | 1.25 | 22.32% | 13.65% |
| FY25-26 | 287.23 | 43.08 | 6.40 | 23.67% | 15.00% |
Quarter on quarter
- Revenue, quarter on quarter
- +28.1%
- Net profit, quarter on quarter
- +50.6%
- Operating margin, quarter on quarter
- +209 bps
Disclosure profile 28 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Acquisition | 2 |
| Press Release | 2 |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 9 |
| Procedural | |
| Newspaper Publication | 4 |
| AGM / EGM | 3 |
| ESOP Allotment | 3 |
| Analyst / Investor Meet | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Record Date | 1 |
| Trading Window | 1 |
| Procedural sub-total | 19 |
| Total | 28 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
28 filings · 9 selected · busiest 2026-07-29
Filing rhythm · the twelve most recent
2026-08-272026-10-09
SelectedProcedural
Filings
28 in the window · 12 earlier on record
-
9 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
1 October 2026 ·
Updates on Acquisition
Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026.
Company Update / Acquisition View filing →
-
30 September 2026 ·
Newspaper Publication
Newspaper Advertisement regarding transfer of Shares to IEPF and Notice of loss of share Certificate
Company Update / Newspaper Publication View filing →
-
30 September 2026 ·
Allotment of ESOP / ESPS
Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022
Company Update / Allotment of ESOP / ESPS View filing →
-
25 September 2026 ·
Closure of Trading Window
Closure of Trading window for the quarter and six months ended September 30, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Press Release / Media Release
Press Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited
Company Update / Press Release / Media Release View filing →
-
23 September 2026 ·
Acquisition
Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.
Company Update / Acquisition View filing →
-
21 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Result and scrutinizer Report of 47th Annual General Meeting.
AGM/EGM / AGM View filing →
-
18 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Summary of Proceedings of 47th Annual General Meeting.
AGM/EGM / AGM View filing →
-
28 August 2026 ·
Newspaper Publication
Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting
Company Update / Newspaper Publication View filing →
-
27 August 2026 ·
Notice Of 47Th Annual General Meeting And Annual Report For The FY 2025-26
Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26
AGM/EGM / AGM View filing →
-
27 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for the Financial year ended March 31, 2026
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
27 August 2026 ·
Reg. 34 (1) Annual Report.
Annual report for Financial Year 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
27 August 2026 ·
Announcement Under Regulation 30-SEBI (LODR) Regulations, 2015
Letter providing a web link of annual report 2025-26 to members.
Company Update / General View filing →
-
24 August 2026 ·
Allotment of ESOP / ESPS
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
Company Update / Allotment of ESOP / ESPS View filing →
-
12 August 2026 ·
Newspaper Publication
Newspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18, 2026
Company Update / Newspaper Publication View filing →
-
4 August 2026 ·
Earnings Call Transcript
Earning Call Transcript for meeting held on July 30, 2026
Company Update / Earnings Call Transcript View filing →
-
30 July 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.
Company Update / Analyst / Investor Meet View filing →
-
30 July 2026 ·
Newspaper Publication
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Company Update / Newspaper Publication View filing →
-
29 July 2026 ·
Change in Management
Change in Senior Management personnel of the Company
Company Update / Change in Management View filing →
-
29 July 2026 ·
Corporate Action- Record Date: September 04, 2026
Corporate Action- Record Date for dividend Purpose: September 04, 2026
Corp. Action / Record Date View filing →
-
29 July 2026 ·
Allotment of ESOP / ESPS
Intimation for grant of Employee Stock Options
Company Update / Allotment of ESOP / ESPS View filing →
-
29 July 2026 ·
Press Release / Media Release
Press Release for Unaudited Financial results for quarter ended June 30, 2026
Company Update / Press Release / Media Release View filing →
-
29 July 2026 ·
Investor Presentation
Press Release for Unaudited Financial Results for quarter ended June 30, 2026
Company Update / Investor Presentation View filing →
-
29 July 2026 ·
Unaudited Results For The Quarter Ended June 30, 2026
Unaudited results along with its Limited Review Report for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
29 July 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On July 29, 2026 Along With Unaudited (Standalone) Financial Results For The Quarter June 30, 2026
Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
22 July 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company, as a ....
Company Update / Analyst / Investor Meet View filing →
-
22 July 2026 ·
Board Meeting Intimation for Prior Intimation Of Board Meeting
Jagsonpal Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the unaudited Financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Jagsonpal Pharmaceuticals Ltd · the 50 most recent filings